Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Vethencourt A, Trinidad EM, Dorca E, Petit A, Soler-Monsó MT, Ciscar M, Barranco A, Pérez-Chacón G, Jimenez M, Rodríguez M, Gomez-Aleza C, Purqueras E, Hernández-Jiménez E, Urruticoechea A, Morilla I, Subirana I, García-Tejedor A, Gil-Gil M, Pernas S, Falo C, Gonzalez-Suarez E

Open source

DOI: 10.1186/s13058-025-01996-w
Published: 2025 May 12
Container: Breast cancer research : BCR
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13058-025-01996-w,
  title = {Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.},
  author = {Vethencourt A and Trinidad EM and Dorca E and Petit A and Soler-Monsó MT and Ciscar M and Barranco A and Pérez-Chacón G and Jimenez M and Rodríguez M and Gomez-Aleza C and Purqueras E and Hernández-Jiménez E and Urruticoechea A and Morilla I and Subirana I and García-Tejedor A and Gil-Gil M and Pernas S and Falo C and Gonzalez-Suarez E},
  year = {2025},
  journal = {Breast cancer research : BCR},
  doi = {10.1186/s13058-025-01996-w},
  url = {https://doi.org/10.1186/s13058-025-01996-w}
}

RIS

TY  - JOUR
TI  - Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
AU  - Vethencourt A
AU  - Trinidad EM
AU  - Dorca E
AU  - Petit A
AU  - Soler-Monsó MT
AU  - Ciscar M
AU  - Barranco A
AU  - Pérez-Chacón G
AU  - Jimenez M
AU  - Rodríguez M
AU  - Gomez-Aleza C
AU  - Purqueras E
AU  - Hernández-Jiménez E
AU  - Urruticoechea A
AU  - Morilla I
AU  - Subirana I
AU  - García-Tejedor A
AU  - Gil-Gil M
AU  - Pernas S
AU  - Falo C
AU  - Gonzalez-Suarez E
PY  - 2025
JO  - Breast cancer research : BCR
DO  - 10.1186/s13058-025-01996-w
UR  - https://doi.org/10.1186/s13058-025-01996-w
ER  -

APA

A, V., EM, T., E, D., A, P., MT, S., M, C., A, B., G, P., M, J., M, R., C, G., E, P., E, H., A, U., I, M., I, S., A, G., M, G., S, P., C, F., & E, G. (2025). Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-025-01996-w

Source records

pubmed · retrieved 2026-09-26T01:38:10.638Z
europe-pmc · retrieved 2026-09-26T01:38:10.662Z
doaj · retrieved 2026-09-26T01:38:10.672Z